Suppr超能文献

甲状腺癌中的融合基因:临床病理特征及其对预后的影响

Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis.

作者信息

Pekova Barbora, Sykorova Vlasta, Mastnikova Karolina, Vaclavikova Eliska, Moravcova Jitka, Vlcek Petr, Lastuvka Petr, Taudy Milos, Katra Rami, Bavor Petr, Kodetova Daniela, Chovanec Martin, Drozenova Jana, Astl Jaromir, Hrabal Petr, Vcelak Josef, Bendlova Bela

机构信息

Department of Molecular Endocrinology, Institute of Endocrinology, 11694 Prague, Czech Republic.

Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, 15006 Prague, Czech Republic.

出版信息

Cancers (Basel). 2021 Apr 16;13(8):1932. doi: 10.3390/cancers13081932.

Abstract

Chromosomal rearrangements of genes are oncogenic driver mutations in thyroid cancer (TC). This study aimed to identify fusion-positive thyroid tumors and to correlate them with clinical and pathological data and determine their prognostic significance. The cohort consisted of 989 different TC samples. Based on the detected mutation, samples were triaged, and those that were positive for a , , , , or mutation were excluded from further analyses. fusion gene testing was performed in 259 cases, including 126 cases using next-generation sequencing. fusion genes were detected in 57 of 846 (6.7%) papillary thyroid carcinomas and in 2 of 10 (20.0%) poorly differentiated thyroid carcinomas. A total of eight types of fusions were found, including , , , , , , and fusion-positive carcinomas were associated with the follicular growth pattern, chronic lymphocytic thyroiditis and lymph node metastases. -rearranged carcinomas showed a higher frequency of multifocality and aggressivity than -rearranged carcinomas. Tumor size, presence of metastases, positivity for the or fusion gene and a late mutation event ( or mutation) were determined as factors affecting patient prognosis. fusion genes are valuable diagnostic and prognostic markers.

摘要

基因的染色体重排是甲状腺癌(TC)中的致癌驱动突变。本研究旨在识别融合阳性甲状腺肿瘤,并将其与临床和病理数据相关联,确定其预后意义。该队列由989个不同的TC样本组成。根据检测到的突变对样本进行分类,那些α、β、γ、δ、ε或ζ突变呈阳性的样本被排除在进一步分析之外。对259例病例进行了RET融合基因检测,其中126例使用下一代测序。在846例乳头状甲状腺癌中有57例(6.7%)检测到RET融合基因,在10例低分化甲状腺癌中有2例(20.0%)检测到。共发现8种类型的RET融合,包括RET-PTC1、RET-PTC2、RET-PTC3、RET-PTC4、RET-PTC5、RET-PTC6、RET-PTC7和RET-PTC8。RET融合阳性癌与滤泡生长模式、慢性淋巴细胞性甲状腺炎和淋巴结转移相关。RET重排癌比NTRK1重排癌表现出更高的多灶性和侵袭性频率。肿瘤大小、转移情况、RET或NTRK1融合基因阳性以及晚期突变事件(α或β突变)被确定为影响患者预后的因素。RET融合基因是有价值的诊断和预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6477/8073383/36177dd48d2d/cancers-13-01932-g001.jpg

相似文献

1
Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis.
Cancers (Basel). 2021 Apr 16;13(8):1932. doi: 10.3390/cancers13081932.
2
, , , , and Fusions in a Large Cohort of Pediatric Papillary Thyroid Carcinomas.
Thyroid. 2020 Dec;30(12):1771-1780. doi: 10.1089/thy.2019.0802. Epub 2020 Jul 1.
3
Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Mod Pathol. 2020 Dec;33(12):2458-2472. doi: 10.1038/s41379-020-0638-5. Epub 2020 Jul 31.
4
Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
Mod Pathol. 2020 Nov;33(11):2186-2197. doi: 10.1038/s41379-020-0574-4. Epub 2020 May 26.
5
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Cancer. 2016 Apr 1;122(7):1097-107. doi: 10.1002/cncr.29887. Epub 2016 Jan 19.
7
Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Diagn Pathol. 2020 Sep 21;15(1):114. doi: 10.1186/s13000-020-01031-w.
9
Clinicopathological features of two cases of rearranged papillary thyroid carcinoma: a case report.
Front Oncol. 2024 May 28;14:1332522. doi: 10.3389/fonc.2024.1332522. eCollection 2024.
10
NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
JCO Precis Oncol. 2021 Jan 14;1. doi: 10.1200/PO.20.00250. eCollection 2021.

引用本文的文献

1
High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma.
Front Oncol. 2025 Aug 25;15:1644562. doi: 10.3389/fonc.2025.1644562. eCollection 2025.
3
Molecular Diagnosis of Thyroid Nodules Using Next-Generation Sequencing in the Chinese Population.
Int J Endocrinol. 2025 Jun 20;2025:7728360. doi: 10.1155/ije/7728360. eCollection 2025.
4
5
Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy.
JCO Precis Oncol. 2025 Jan;9:e2400321. doi: 10.1200/PO.24.00321. Epub 2025 Feb 21.
6
Hidden in Plain Sight: Incidental Diagnosis of Metastatic Papillary Thyroid Microcarcinoma Without Radiologically Apparent Thyroid Tumor.
AACE Clin Case Rep. 2024 Nov 2;11(1):58-61. doi: 10.1016/j.aace.2024.10.006. eCollection 2025 Jan-Feb.
7
Distinctive role of mutations in distant metastatic thyroid cancer.
Chin J Cancer Res. 2024 Dec 30;36(6):700-712. doi: 10.21147/j.issn.1000-9604.2024.06.08.
8
New Horizons of Biomarkers in Metastatic Thyroid Cancer.
J Cancer. 2025 Jan 1;16(1):241-264. doi: 10.7150/jca.101395. eCollection 2025.
9
Worse survival and higher rates of relapse in U.S. Armenians with papillary thyroid cancer.
Laryngoscope Investig Otolaryngol. 2024 Dec 20;9(6):e70052. doi: 10.1002/lio2.70052. eCollection 2024 Dec.
10
The role of genetic and epigenetic modifications as potential biomarkers in the diagnosis and prognosis of thyroid cancer.
Front Oncol. 2024 Nov 4;14:1474267. doi: 10.3389/fonc.2024.1474267. eCollection 2024.

本文引用的文献

3
Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Mod Pathol. 2020 Dec;33(12):2458-2472. doi: 10.1038/s41379-020-0638-5. Epub 2020 Jul 31.
4
The Impact of BRAF Mutation on the Recurrence of Papillary Thyroid Carcinoma: A Meta-Analysis.
Cancers (Basel). 2020 Jul 25;12(8):2056. doi: 10.3390/cancers12082056.
5
, , , , and Fusions in a Large Cohort of Pediatric Papillary Thyroid Carcinomas.
Thyroid. 2020 Dec;30(12):1771-1780. doi: 10.1089/thy.2019.0802. Epub 2020 Jul 1.
6
Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
Mod Pathol. 2020 Nov;33(11):2186-2197. doi: 10.1038/s41379-020-0574-4. Epub 2020 May 26.
7
BRAF Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence.
World J Surg. 2020 Aug;44(8):2685-2691. doi: 10.1007/s00268-020-05521-2.
9
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Lancet Oncol. 2020 Apr;21(4):531-540. doi: 10.1016/S1470-2045(19)30856-3. Epub 2020 Feb 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验